Mohammad Golparian, MD
Internal Medicine · Prescott, AZNPI 1174510002
Payments from drug & device makers
Across 126 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$307
- Amgen$277
- Abbott$185
- AbbVie$175
- AstraZeneca$155
- GSK$149
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,291100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 18 | $307 |
| Amgen(2 entities) | 16 | $277 |
| Abbott | 9 | $185 |
| AbbVie(2 entities) | 10 | $175 |
| AstraZeneca | 11 | $155 |
| GSK | 9 | $149 |
| Paratek Pharmaceuticals, Inc. | 3 | $106 |
| Lilly USA, LLC | 5 | $88 |
| Stryker | 1 | $59 |
| Sanofi-aventis U.S. LLC | 4 | $57 |
| Bayer | 2 | $53 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $51 |
| Scilex Pharmaceuticals Inc. | 3 | $48 |
| Lucid Diagnostics Inc. | 1 | $46 |
| Exact Sciences | 2 | $46 |
| Dexcom, Inc. | 2 | $45 |
| Astellas Pharma US Inc | 2 | $43 |
| Kowa Pharmaceuticals America, Inc. | 3 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Pfizer | 2 | $32 |
| Phadia US Inc. | 2 | $30 |
| Radius Health, Inc. | 1 | $25 |
| Boston Scientific | 1 | $23 |
| Sumitomo Pharma America, Inc. | 2 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $22 |
| Neurelis, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $17 |
| Alfasigma USA, Inc. | 1 | $16 |
| Bioventus LLC | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Team_makena_llc | 1 | $14 |
| GE HealthCare | 1 | $14 |
| Tactile Systems Technology Inc | 1 | $14 |
| Merck | 1 | $12 |
| Esperion Therapeutics, Inc. | 1 | $11 |
How this compares
$2,291 in reported general payments places this provider in the 85th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 75 | $103,584 |
| OzempicSemaglutide | 62 | $89,712 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $61,998 |
| MounjaroTirzepatide | 40 | $52,378 |
| TrulicityDulaglutide | 18 | $34,037 |
| FarxigaDapagliflozin Propanediol | 26 | $32,036 |
| JanuviaSitagliptin Phosphate | 23 | $28,973 |
| XareltoRivaroxaban | 26 | $24,152 |
| JardianceEmpagliflozin | 16 | $20,522 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $19,193 |
| MyrbetriqMirabegron | 21 | $15,046 |
| Repatha SyringeEvolocumab | 14 | $12,852 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $12,806 |
| Humalog Kwikpen U-200Insulin Lispro | 15 | $12,641 |
| Nurtec OdtRimegepant Sulfate | 11 | $9,961 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt, Paxlovid | $32 | $116,404130 claims |
| Lilly USA, LLCMounjaro, Trulicity | $88 | $86,41658 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $149 | $81,19070 claims |
| AstraZenecaFarxiga | $155 | $32,03626 claims |
| MerckJanuvia | $12 | $28,97323 claims |
| Boehringer IngelheimJardiance | $19 | $20,52216 claims |
| Astellas Pharma US IncMyrbetriq | $43 | $15,04621 claims |
| Sanofi-aventis U.S. LLCLantus | $57 | $6,37121 claims |
| AbbVieSynthroid | $175 | $2,91440 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Prescott
- Yessica SachdevaMesa$13.7M
- Louise TaberPhoenix$8.5M
- Janelle WeyerChandler$5.5M
- Robert MutterperlTucson$5.3M
- Jalal AbbasSun City West$4.8M
- Nebojsa SkrepnikTucson$4.7M
- Philip MathewTempe$4.1M
- Justin MoserScottsdale$3.9M
- Franz RischardTucson$3.7M
- Randall SeveranceChandler$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.